Cytosponge™ Feasibility Study in Tanzania

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

101 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-24

Study Completion Date

2020-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Tanzanian pilot study to test the feasibility of using the Cytosponge™ device - a less-invasive endoscopy alternative - for research on esophageal squamous cell carcinoma in African settings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma

NCT06429865

Esophageal Squamous Cell Carcinoma

ENROLLING_BY_INVITATION NA

Esophageal Squamous Cell Cancer Surveillance With Cytosponge

NCT04192695

Esophageal Cancer

COMPLETED NA

Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer

NCT03529669

Oesophageal Cancer

COMPLETED NA

Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma

NCT05028725

Esophageal Squamous Cell Carcinoma Esophageal Squamous Dysplasia

RECRUITING NA

C2 Esophageal Squamous Epithelium Dysplasia

NCT05349240

Esophageal Squamous Epithelium Dysplasia

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Cytosponge™ consists of a spherical mesh enclosed in a gelatine capsule and attached to a string. The capsule is swallowed with the use of water and allowed to reach the stomach while remaining attached to the suture which is held onto by the patient or nurse (and which is affixed to a card preventing inadvertent swallowing of the suture). In the stomach the capsule is left for up to 5 minutes where it dissolves allowing the sponge to expand to its full size. It is then withdrawn using the suture, and as it does so collects cells from the lining of the oesophagus. After retrieval the Cytosponge™ containing the cytological specimen placed in preservative fluid. The typical cell yield of the procedure is 250,000. These cells are used to prepare a clot which is fixed with formalin and embedded in paraffin for sectioning and slide preparation. Slides are then examined under a microscope for pathological diagnosis and characterisation. This device was approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in 2008 and is a Class 1 device according to European Medical Devices 93/42/EEC as implemented in the United Kingdom by The Medical Devices Regulations 2002 (SI No 618).

Healthy adult (\>30 years) volunteers will be recruited during routine visits to the Majengo Healthcare Centre in Moshi, Tanzania where they will be informed of the study and invited to participate. Their participation will then involve the following:

* Completing a short lifestyle questionnaire.
* Swallowing the Cytosponge™ device to collect cells from their oesophagus.
* Being contacted by telephone 7-days post procedure to assess acceptability.

The following endpoints will be investigated:

Core:

* Response rate of participants invited to swallow device.
* Proportion of participants able to swallow the device within three attempts and number of attempts taken (frequency distribution of 1, 2 and 3 attempts).
* Post-swallow acceptability of device as per a previously employed satisfaction score (graded 0-10)
* Proportion of collected sponges successfully processed into paraffin blocks.
* Prevalence of ESD as determined by examination by a trained pathologist.
* Prevalence of benign oesophageal pathologies (inflammation, candidiasis, eosinophilic oesophagitis).

Extended (subject to future funding):

* Prevalence of positivity for antibodies against chemical exposures and proliferation markers.
* DNA yield from cells collected from the device.
* DNA methylation profiles.
* Genetic mutations in candidate cancer-relevant gene panel.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Diseases Esophagus SCC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Healthy community volunteers will be invited to participate in the study , complete and questionnaire and swallow the cytosponge. Participation rates and acceptability of device administration will be assess in this single group.

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cytosponge™

Single intervention arm of feasibility study

Group Type OTHER

Cytosponge™

Intervention Type DEVICE

The device consists of a spherical mesh enclosed in a gelatine capsule and attached to a string. The capsule is swallowed and allowed to reach the stomach . In the stomach the capsule is left for up to 5 minutes where it dissolves allowing the sponge to expand to its full size. It is then withdrawn using the suture, and as it does so collects cells from the lining of the oesophagus.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cytosponge™

The device consists of a spherical mesh enclosed in a gelatine capsule and attached to a string. The capsule is swallowed and allowed to reach the stomach . In the stomach the capsule is left for up to 5 minutes where it dissolves allowing the sponge to expand to its full size. It is then withdrawn using the suture, and as it does so collects cells from the lining of the oesophagus.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 30 years or older.
* Resident of Kilimanjaro Region for 10 years or more.

Exclusion Criteria

* Eaten or drank within the last 4 hours.
* Known current pregnancy.
* Objection to CytoSCCAPE data collection.
* Symptoms of dysphagia (difficulty swallowing).
* Recorded history of oropharyngeal, esophageal or gastric cancer
* Received prior surgical intervention to the esophagus.
* Esophageal varices, stricture or requiring esophageal dilation.
* Recorded cirrhosis of the liver.
* Swallowing difficulty due to cerebrovascular accident or neurological disorder.
* Recent history of vomiting blood.
* Recent use of anticoagulation therapy/medication.
* Myocardial infarction or any cardiac event within the last 6 months.
* Lacking capacity to provide informed consent.
* Unwilling to swallow beef gelatine capsule due to dietary preferences.

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes